Multiple Myeloma Challenges and Treatment Evolution

Opinion
Video

Gabriel Hinojosa, PharmD, BCOP, explores unmet needs and social determinants in multiple myeloma care, envisioning treatment advancements amid evolving complexities and patient disparities.

This is a video synopsis/summary of an Insights involving Gabriel Hinojosa, PharmD, BCOP.

Hinojosa highlighted the prominent unmet need in multiple myeloma management: the absence of a cure and eventual exhaustion of treatment options. Despite recent additions to the treatment arsenal, achieving a cure remains elusive. The treatment landscape is evolving with the identification of new targets such as BCMA and GPRC5D, offering promising response rates. Bispecifics and chimeric antigen receptor T-cell agents have revolutionized patient treatment, with more in the pipeline, requiring continuous exploration of optimal sequencing and toxicity management. Social determinants of health significantly impact outcomes, especially for patients with lower incomes and limited resources, leading to challenges in medication adherence, treatment schedules, and financial toxicity. Addressing these social determinants is a crucial unmet need to enhance overall care for patients with multiple myeloma.

This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.

Related Videos
Video 2 - "Achieving Post-Discharge Success: Goals in Hepatic Encephalopathy Care"
Video 1 - "Identifying and Screening for Hepatic Encephalopathy Risk Factors"
Video 15 - "Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM  "
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 11 - "Complying with REMS Training and Documentation Requirements"
Video 09 - "Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma"
Video 09 - "Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma"
Related Content
© 2024 MJH Life Sciences

All rights reserved.